Spanish registry of adults with IgM monoclonal gammopathies including Waldenström macroglobulinemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, observational, multicenter registry compiling data on adults diagnosed in Spain with IgM monoclonal gammopathies (MGUS‑IgM), asymptomatic Waldenström macroglobulinemia, or symptomatic Waldenström macroglobulinemia over the past 30 years. Participating hospitals will contribute clinical characteristics, diagnostic findings, treatment regimens, adverse events, and follow‑up outcomes to a central database. The project will describe patterns of care, long‑term safety and effectiveness of different therapies, and provide estimates of incidence and prognosis in the Spanish population. Data will be abstracted from medical records at participating centers and analyzed using descriptive statistics and survival/outcome comparison methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Patients having a confirmed diagnosis of either in the las 30 years:
* Monoclonal Gammopathy of uncertain significance -IgM
* Asymptomatic Waldenström's macroglobulinemia
* Symptomatic Waldenström's macroglobulinemia

Exclusion Criteria:

* Other subtypes of Lymphoproliferative diseases.

Where it's running

• Hospital de Mérida
  Mérida, Badajoz, Spain Recruiting
• Hospital Son Llatzer
  Palma, Balearic Islands, Spain Recruiting
• Hospital Universitario Son Espases
  Palma de Mallorca, Balearic Islands, Spain Recruiting
• ICO Badalona - Hospital Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Mutua Terrassa
  Barcelona, Barcelona, Spain Recruiting
• Hospital de San Juan Despí Moisès Broggi
  Barcelona, Barcelona, Spain Recruiting

+1 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Ramon Garcia Sanz, Md
• Email: rgarcias@usal.es
• Phone: +34 915868000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirtobrutinib combined with venetoclax and rituximab for Waldenström's macroglobulinemia

  This treatment tries combining pirtobrutinib, venetoclax, and rituximab in people newly diagnosed with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma to see if it controls the disease.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT07231952

• New therapy dose test for people with prior B-cell cancers

  This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.

  Recruiting at 25 sites Phase 1 Eli Lilly and Company · Duarte, California and 50 other locations · NCT07101328

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Zanubrutinib with bendamustine and rituximab for untreated Waldenström macroglobulinemia

  This treatment will try zanubrutinib together with bendamustine and rituximab to see if it produces deep responses in people with untreated Waldenström macroglobulinemia.

  Recruiting at 5 sites Phase 2 Massachusetts General Hospital · Denver, Colorado and 4 other locations · NCT06561347

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Using epcoritamab to treat previously treated Waldenstrom Macroglobulinemia

  This study is testing if a new treatment called epcoritamab can help people with Waldenstrom Macroglobulinemia who have already received other treatments.

  Recruiting at 3 sites Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 2 other locations · NCT06510491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.